Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Clazakizumab dose-ranging study in active psoriatic arthritis
2011-004016-29Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in psoriatic arthritis (PsA) comparing Clazakizumab plus methotrexate with Placebo plus methotrexate (2 arms). Primary endpoint: ACR20 response. Started Dec 2011; status: terminated.
02
Drugs
clazakizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2011-004016-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004016-29.